Truglif 10mg Tablet

Truglif 10mg Tablet contains the active ingredient Empagliflozin, which belongs to a class of medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. Empagliflozin works by inhibiting the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose back into the bloodstream. By blocking this protein, Empagliflozin helps the kidneys remove excess glucose from the body through urine, thereby lowering blood sugar levels.

Uses:

Truglif 10mg Tablet is primarily prescribed for the management of type 2 diabetes mellitus. It helps improve glycemic control by lowering blood glucose levels in adults with diabetes. By enhancing urinary glucose excretion, Empagliflozin helps reduce hyperglycemia and its associated complications.

Benefits:

• Blood sugar control: Empagliflozin helps lower blood glucose levels by promoting the excretion of excess glucose in the urine, leading to improved glycemic control.
• Cardiovascular benefits: Clinical studies have shown that Empagliflozin may reduce the risk of cardiovascular events, including heart attacks, strokes, and cardiovascular-related death, in patients with type 2 diabetes and established cardiovascular disease.
• Weight loss: Empagliflozin may lead to modest weight loss in some patients due to the calorie loss associated with urinary glucose excretion.

Dosage and Administration:

The usual recommended dose of Truglif 10mg Tablet is 10mg taken orally once daily, with or without food. It is important to follow the dosage instructions provided by the healthcare provider. The tablet should be swallowed whole with a glass of water and should not be crushed, chewed, or split.

Precautions:

• Renal function: Truglif 10mg Tablet should be used with caution in patients with impaired renal function. Dose adjustments may be necessary based on the individual’s estimated glomerular filtration rate (eGFR).
• Hypotension: Empagliflozin may cause a decrease in blood pressure, especially in patients with a history of hypotension or those taking antihypertensive medications. Blood pressure should be monitored regularly during treatment.
• Genital mycotic infections: Patients taking Empagliflozin may be at increased risk of genital mycotic infections (e.g., yeast infections). Proper hygiene practices and prompt treatment of any infections are recommended.
• Diabetic ketoacidosis: Patients should be advised about the symptoms of diabetic ketoacidosis (e.g., excessive thirst, frequent urination, nausea, vomiting, abdominal pain) and instructed to seek medical attention if these symptoms occur.

In Summary:

Truglif 10mg Tablet contains Empagliflozin, a medication used for the management of type 2 diabetes mellitus. By inhibiting the SGLT2 protein in the kidneys, Empagliflozin helps lower blood glucose levels and may provide additional cardiovascular benefits. It is taken orally once daily and should be used with caution in patients with renal impairment.